Managers / Q4 2025 · view latest →
BOSTON RESEARCH & MANAGEMENT INC
CIK 0001259261 · 40 BEACH STREET, SUITE 200, MANCHESTER, MA, 01944 · 978-526-9700
Summary
Boston Research & Management Inc reported $434M in U.S.-listed holdings across 120 positions for Q4 2025.
Its largest position, IVV, represents 5.0% of the portfolio.
Compared with Q3 2025, the fund opened 5 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 56.5% · $245M
- Other · 28.3% · $123M
- ETP · 15.2% · $66M
- REIT · 0.1% · $327,000
- Ltd Part · 0.0% · $67,000
Quarter-over-Quarter Changes full breakdown →
vs Q3 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| IYKiShares US Consumer Staples ET | NEW | +10.5K | 10.5K | +$702,000 | $702,000 |
| AMATApplied Materials Inc | NEW | +975 | 975 | +$250,000 | $250,000 |
| CHRWCH Robinson Worldwide Inc | NEW | +1.4K | 1.4K | +$223,000 | $223,000 |
| Yum China Holding Inc. | NEW | +4.4K | 4.4K | +$209,000 | $209,000 |
| CVSCVS Health Corp | NEW | +2.5K | 2.5K | +$201,000 | $201,000 |
| PFFiShares US Preferred Stock | ADDED | +17.2K | 31.2K | +$524,000 | $964,000 |
| BBHVanEck Vectors Biotech ETF | SOLD OUT | −10.4K | 0 | −$2M | $0 |
| IBBiShares Nasdaq Biotechnology I | SOLD OUT | −11.0K | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $421M | 114 | Apr 10, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $434M | 120 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $453M | 119 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $418M | 116 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $403M | 116 | May 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $407M | 115 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $426M | 115 | Nov 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $395M | 114 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $405M | 116 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $377M | 114 | Feb 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $338M | 114 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $353M | 113 | Aug 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $335M | 110 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $323M | 106 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $294M | 102 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $309M | 106 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $344M | 111 | May 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $366M | 112 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $336M | 108 | Nov 10, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2021 | $330M | 108 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $311M | 105 | May 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $287M | 104 | Feb 9, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $256M | 101 | Nov 9, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $241M | 97 | Aug 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $199M | 92 | May 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $267M | 101 | Feb 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $253M | 99 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $247M | 99 | Aug 7, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $240M | 104 | May 7, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.